Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model
Gaspar J. Kitange(University of California, San Francisco), Jann N. Sarkaria(Mayo Clinic), Jan C. Buckner(McGill University), Brett L. Carlson(University of California, San Francisco), Paul A. Decker(University of California, San Francisco), C. David James(Northwestern University), Karla V. Ballman(National Cancer Institute), Ann C. Mladek(Mayo Clinic), Patrick T. Grogan, Mark A. Schroeder(MACOM (United States)), Caterina Giannini(Mayo Clinic), Wenting Wu(Wenzhou Institute of Industrial Science)
Cited by 97
Related Papers
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
|Journal of Clinical Oncology|2012|1.2k
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
|New England Journal of Medicine|2016|1k
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|New England Journal of Medicine|2016|783